S&P 500 7,500.58 ▲ 80.48 (+1.08%) DOW 51,564.70 ▲ 72.15 (+0.14%) NASDAQ 26,517.93 ▲ 496.28 (+1.91%) US Markets Closed â€ĸ 01:07 AM ET

SLN

Silence Therapeutics plc

Price Chart
Latest Quote

$6.93

+0.17 (+2.51%)
Current Price
Previous Close $6.76
Open $6.82
Day High $7.00
Day Low $6.52
Volume 382,303
Fetched: 2026-06-18T20:38:21
Stock Information
Shares Outstanding 47.23M
Total Debt $136K
Cash Equivalents $70.08M
Revenue $839K
Net Income $-75.04M
Sector Healthcare
Industry Biotechnology
Market Cap $327.34M
EPS (TTM) $-1.62
Exchange NGM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$247.00M
Sales$839K
Income$-75.04M
Book/sh$1.05
Cash/sh$1.48
Employees88
Financial Ratios
Quick Ratio8.82
Current Ratio9.83
Debt/Eq0.28
Returns & Margins
ROA-29.79%
ROE-92.56%
Gross Margin79.50%
Operating Margin-3565.40%
Ownership
Insider Ownership24.38%
Institutional Ownership44.51%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E-17.77
P/S390.15
P/B6.63
Analyst Data
Recommendationbuy
Target Price$31.20
Technical Indicators
SMA20$nan
SMA50$nan
SMA200$nan
RSI47.89
ATRnan
Shares Float24.92M
Short Float5.76%
Short Ratio9.62
Volatility1.48
Rel Volume1.56
Performance History
Weeknan%
Monthnan%
Quarternan%
6 Monthsnan%
YTDnan%
Yearnan%
3 Yearsnan%
5 Yearsnan%
10 Yearsnan%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-06-18 $6.93 382,900
2026-06-17 $6.76 341,300
2026-06-16 $6.71 216,800
2026-06-15 $7.00 406,300
2026-06-12 $6.69 239,400
2026-06-11 $6.68 700,900
2026-06-10 $6.00 140,900
2026-06-09 $6.01 183,400
2026-06-08 $6.23 77,400
2026-06-05 $6.17 160,500
2026-06-04 $6.85 197,300
2026-06-03 $6.41 119,800
2026-06-02 $6.37 193,000
2026-06-01 $6.53 277,900
2026-05-29 $6.90 210,100
2026-05-28 $6.86 114,600
2026-05-27 $6.80 326,300
2026-05-26 $6.64 217,400
2026-05-22 $6.20 258,000
2026-05-21 $6.49 130,100
2026-05-20 $6.24 170,100
2026-05-19 $5.77 269,600
About Silence Therapeutics plc

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

Period:
Loading...
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Reconciled Cost Of Revenue $215,000 $11,810,000 $12,867,000 $13,463,000
Cost Of Revenue $215,000 $11,810,000 $12,867,000 $13,463,000
Total Revenue $559,000 $43,258,000 $31,643,000 $21,655,000
Operating Revenue $559,000 $43,258,000 $31,643,000 $21,655,000
Expenses
Total Expenses $90,312,000 $106,577,000 $96,026,000 $82,695,000
Other Income Expense $-2,328,000 $14,383,000 $9,308,000 $11,114,000
Other Non Operating Income Expenses $7,463,000 $13,737,000 $11,949,000 $9,820,000
Net Non Operating Interest Income Expense $3,480,000 $4,472,000 $1,803,000 $280,000
Operating Expense $90,097,000 $94,767,000 $83,159,000 $69,232,000
General And Administrative Expense $22,344,000 $26,884,000 $26,222,000 $25,682,000
Other Operating Expenses - $-13,737,000 $-11,949,000 $-9,820,000
Interest Expense - - $43,313 $56,879
Interest Expense Non Operating - - $43,313 $56,879
Rent Expense Supplemental - - - $410,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-88,612,000 $-45,309,000 $-54,228,000 $-50,334,000
Net Interest Income $3,480,000 $4,472,000 $1,803,000 $280,000
Interest Income $3,480,000 $4,472,000 $1,803,000 $280,000
Normalized Income $-81,268,750 $-45,793,500 $-52,088,790 $-51,382,140
Net Income From Continuing And Discontinued Operation $-88,612,000 $-45,309,000 $-54,228,000 $-50,334,000
Total Operating Income As Reported $-91,077,000 $-63,319,000 $-64,383,000 $-61,040,000
Net Income Common Stockholders $-88,612,000 $-45,309,000 $-54,228,000 $-50,334,000
Net Income $-88,612,000 $-45,309,000 $-54,228,000 $-50,334,000
Net Income Including Noncontrolling Interests $-88,612,000 $-45,309,000 $-54,228,000 $-50,334,000
Net Income Continuous Operations $-88,612,000 $-45,309,000 $-54,228,000 $-50,334,000
Pretax Income $-88,601,000 $-44,464,000 $-53,272,000 $-49,646,000
Special Income Charges $-1,324,000 $0 - -
Interest Income Non Operating $3,480,000 $4,472,000 $1,803,000 $280,000
Operating Income $-89,753,000 $-63,319,000 $-64,383,000 $-61,040,000
Gross Profit $344,000 $31,448,000 $18,776,000 $8,192,000
Per Share
Diluted EPS $-1.89 $-0.99 $-1.47 $-1.56
Basic EPS $-1.89 $-0.99 $-1.47 $-1.56
Other
Tax Effect Of Unusual Items $-2,447,750 $161,500 $-501,790 $245,860
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-79,407,000 $-63,372,000 $-61,121,000 $-61,738,000
Total Unusual Items $-9,791,000 $646,000 $-2,641,000 $1,294,000
Total Unusual Items Excluding Goodwill $-9,791,000 $646,000 $-2,641,000 $1,294,000
Reconciled Depreciation $555,000 $593,000 $621,000 $596,000
EBITDA (Bullshit earnings) $-89,198,000 $-62,726,000 $-63,762,000 $-60,444,000
EBIT $-89,753,000 $-63,319,000 $-64,383,000 $-61,040,000
Diluted Average Shares $47,231,567 $46,250,741 $37,092,417 $32,194,837
Basic Average Shares $47,231,567 $46,250,741 $37,092,417 $32,194,837
Diluted NI Availto Com Stockholders $-88,612,000 $-45,309,000 $-54,228,000 $-50,334,000
Tax Provision $11,000 $845,000 $956,000 $688,000
Restructuring And Mergern Acquisition $1,324,000 $0 - -
Gain On Sale Of Security $-8,467,000 $646,000 $-2,641,000 $1,294,000
Research And Development $67,753,000 $67,883,000 $56,937,000 $43,550,000
Selling General And Administration $22,344,000 $26,884,000 $26,222,000 $25,682,000
Other Gand A $22,344,000 $26,884,000 $26,222,000 $25,682,000
Other Taxes - $-13,737,000 $-11,949,000 $-9,820,000
Fetched: 2026-06-18
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $51,395,000 $124,319,000 $11,650,000 $16,631,773
Total Assets $131,442,000 $202,635,000 $119,448,000 $130,096,453
Total Non Current Assets $12,784,000 $15,269,000 $16,297,000 $13,087,098
Non Current Prepaid Assets $127,000 $3,234,000 $3,284,000 $0
Goodwill And Other Intangible Assets $10,909,000 $9,704,000 $10,343,000 $10,079,752
Other Intangible Assets $288,000 $312,000 $362,000 $387,264
Current Assets $118,658,000 $187,366,000 $103,151,000 $117,009,355
Prepaid Assets $8,930,000 $13,124,000 $10,385,000 $9,923,636
Receivables $24,614,000 $26,908,000 $23,977,000 $20,987,281
Other Receivables $22,007,000 $24,396,000 $22,442,000 -
Taxes Receivable $2,607,000 $1,540,000 $1,245,000 $19,879,948
Accounts Receivable $0 $972,000 $290,000 $1,107,333
Cash Cash Equivalents And Short Term Investments $85,114,000 $147,334,000 $68,789,000 $86,098,438
Cash And Cash Equivalents $11,277,000 $121,330,000 $68,789,000 $66,338,299
Cash Equivalents $0 $64,740,000 $36,970,000 $15,526,860
Cash Financial $11,277,000 $56,590,000 $31,819,000 $50,811,439
Investmentin Financial Assets - - $361,788 $343,697
Debt
Total Debt $160,000 $117,000 $346,000 $539,749
Long Term Debt And Capital Lease Obligation $71,000 $0 $118,000 $0
Current Debt And Capital Lease Obligation $89,000 $117,000 $228,000 $539,749
Liabilities
Total Liabilities Net Minority Interest $69,138,000 $68,612,000 $97,455,000 $103,384,928
Total Non Current Liabilities Net Minority Interest $55,525,000 $51,790,000 $75,119,000 $76,829,519
Non Current Deferred Liabilities $55,454,000 $51,790,000 $75,001,000 $76,829,519
Current Liabilities $13,613,000 $16,822,000 $22,336,000 $26,555,409
Current Deferred Liabilities $168,000 $306,000 $6,571,000 $10,727,209
Payables And Accrued Expenses $10,392,000 $12,954,000 $12,403,000 $15,288,451
Payables $4,643,000 $4,593,000 $4,556,000 $5,133,667
Total Tax Payable $234,000 $896,000 $1,208,000 $1,277,971
Income Tax Payable $39,000 $652,000 $474,000 $712,808
Accounts Payable $4,409,000 $3,697,000 $3,348,000 $3,855,696
Equity
Common Stock Equity $62,304,000 $134,023,000 $21,993,000 $26,711,525
Total Equity Gross Minority Interest $62,304,000 $134,023,000 $21,993,000 $26,711,525
Stockholders Equity $62,304,000 $134,023,000 $21,993,000 $26,711,525
Gains Losses Not Affecting Retained Earnings $-2,976,000 $-11,781,000 $-10,725,000 $29,447,786
Other Equity Adjustments $-2,976,000 $-11,781,000 $-10,725,000 $26,924,520
Retained Earnings $-562,572,000 $-474,044,000 $-431,894,000 $-318,600,767
Other Equity Interest - - $44,433,687 $28,739,819
Other
Ordinary Shares Number $141,701,848 $141,674,074 $118,846,966 $107,808,471
Share Issued $141,701,848 $141,674,074 $118,846,966 $107,808,471
Tangible Book Value $51,395,000 $124,319,000 $11,650,000 $16,631,773
Invested Capital $62,304,000 $134,023,000 $21,993,000 $26,711,525
Working Capital $105,045,000 $170,544,000 $80,815,000 $90,453,946
Capital Lease Obligations $160,000 $117,000 $346,000 $539,749
Total Capitalization $62,304,000 $134,023,000 $21,993,000 $26,711,525
Additional Paid In Capital $617,562,000 $609,560,000 $455,765,000 $280,601,711
Capital Stock $10,290,000 $10,288,000 $8,847,000 $6,522,976
Common Stock $10,290,000 $10,288,000 $8,847,000 $6,522,976
Non Current Deferred Revenue $55,454,000 $51,790,000 $75,001,000 $76,829,519
Long Term Capital Lease Obligation $71,000 $0 $118,000 $0
Current Deferred Revenue $168,000 $306,000 $6,571,000 $10,727,209
Current Capital Lease Obligation $89,000 $117,000 $228,000 $539,749
Pensionand Other Post Retirement Benefit Plans Current $2,964,000 $3,445,000 $3,134,000 -
Current Accrued Expenses $5,749,000 $8,361,000 $7,847,000 $10,154,785
Goodwill $10,621,000 $9,392,000 $9,981,000 $9,692,488
Net PPE $1,748,000 $2,331,000 $2,670,000 $2,663,649
Accumulated Depreciation $-3,961,000 $-4,525,000 $-4,498,000 $-3,973,085
Gross PPE $5,709,000 $6,856,000 $7,168,000 $6,636,734
Construction In Progress $0 $356,000 $362,000 -
Other Properties $167,000 $157,000 $370,000 $602,679
Machinery Furniture Equipment $5,542,000 $6,343,000 $6,436,000 $6,034,055
Other Short Term Investments $73,837,000 $26,004,000 $0 $19,760,138
Foreign Currency Translation Adjustments - - $2,485,382 $2,523,266
Investments And Advances - - $361,788 $343,697
Available For Sale Securities - - $361,788 $343,697
Fetched: 2026-06-18
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $-62,326,000 $-67,851,000 $-49,518,000 $-57,589,000
Operating Activities
Operating Cash Flow $-62,271,000 $-67,640,000 $-49,462,000 $-57,044,000
Cash Flow From Continuing Operating Activities $-62,271,000 $-67,640,000 $-49,462,000 $-57,044,000
Operating Gains Losses $11,022,000 $-2,581,000 $3,962,000 $-1,003,000
Investing Activities
Capital Expenditure $-55,000 $-211,000 $-56,000 $-545,000
Investing Cash Flow $-47,992,000 $-21,966,000 $19,294,000 $-20,498,000
Cash Flow From Continuing Investing Activities $-47,992,000 $-21,966,000 $19,294,000 $-20,498,000
Financing Activities
Issuance Of Capital Stock $15,000 $142,087,000 $31,937,000 $52,581,000
Financing Cash Flow $15,000 $142,087,000 $31,937,000 $52,581,000
Cash Flow From Continuing Financing Activities $15,000 $142,087,000 $31,937,000 $52,581,000
Net Common Stock Issuance $15,000 $142,087,000 $31,937,000 $52,581,000
Common Stock Issuance $15,000 $142,087,000 $31,937,000 $52,581,000
Other
Income Tax Paid Supplemental Data $637,000 $433,000 $801,000 $0
End Cash Position $11,277,000 $121,330,000 $68,789,000 $66,271,000
Beginning Cash Position $121,330,000 $68,789,000 $66,271,000 $99,351,000
Effect Of Exchange Rate Changes $195,000 $60,000 $749,000 $-8,119,000
Changes In Cash $-110,248,000 $52,481,000 $1,769,000 $-24,961,000
Net Investment Purchase And Sale $-47,937,000 $-21,755,000 $19,350,000 $-19,953,000
Sale Of Investment $118,476,000 $117,412,000 $45,121,000 $0
Purchase Of Investment $-166,413,000 $-139,167,000 $-25,771,000 $-19,953,000
Net PPE Purchase And Sale $-55,000 $-211,000 $-56,000 $-173,000
Purchase Of PPE $-55,000 $-211,000 $-56,000 $-173,000
Change In Working Capital $10,159,000 $-33,023,000 $-15,244,000 $-19,397,000
Change In Other Working Capital $-334,000 $-28,786,000 $-10,323,000 $-5,443,000
Change In Other Current Liabilities $-168,000 $-165,000 $-175,000 $-235,000
Change In Other Current Assets $9,674,000 $-1,330,000 $-1,262,000 $-5,199,000
Change In Payables And Accrued Expense $-4,078,000 $499,000 $-473,000 $2,024,000
Change In Payable $-4,078,000 $499,000 $-473,000 $2,024,000
Change In Receivables $5,065,000 $-3,241,000 $-3,011,000 $-10,544,000
Changes In Account Receivables $1,024,000 $-904,000 $392,000 $-723,000
Other Non Cash Items $-3,480,000 $-4,472,000 $-1,803,000 $-280,000
Stock Based Compensation $8,074,000 $16,307,000 $16,274,000 $12,686,000
Deferred Tax $11,000 $845,000 $956,000 $688,000
Deferred Income Tax $11,000 $845,000 $956,000 $688,000
Depreciation Amortization Depletion $555,000 $593,000 $621,000 $596,000
Depreciation And Amortization $555,000 $593,000 $621,000 $596,000
Amortization Cash Flow $243,000 $257,000 $252,000 $217,000
Amortization Of Intangibles $243,000 $257,000 $252,000 $217,000
Depreciation $312,000 $336,000 $369,000 $379,000
Net Foreign Currency Exchange Gain Loss $11,022,000 $-2,581,000 $3,962,000 $-1,003,000
Net Income From Continuing Operations $-88,612,000 $-45,309,000 $-54,228,000 $-50,334,000
Net Intangibles Purchase And Sale - $0 $0 $-372,000
Purchase Of Intangibles - $0 $0 $-372,000
Repayment Of Debt - - $-221,659 $-229,938
Net Issuance Payments Of Debt - - $-221,659 $-229,938
Net Long Term Debt Issuance - - $-221,659 $-229,938
Long Term Debt Payments - - $-221,659 $-229,938
Interest Received Cfi - - $1,220,398 $27,835
Taxes Refund Paid - - $7,912,203 $0
Sale Of PPE - - - $0
Gain Loss On Sale Of PPE - - - $0
Fetched: 2026-06-18